175 related articles for article (PubMed ID: 35874685)
21. Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
Sigmund AM; Denlinger N; Huang Y; Bond D; Voorhees T; Bajwa A; Elder P; Brammer JE; Saad A; Penza S; Vasu S; de Lima M; Jaglowski S; Kittai AS
Transplant Cell Ther; 2022 Jun; 28(6):342.e1-342.e5. PubMed ID: 35248778
[TBL] [Abstract][Full Text] [Related]
22. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ; Gu T; Jun MP; McBride A
Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
[TBL] [Abstract][Full Text] [Related]
23. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
24. Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study.
Mao Y; Huang L; Ruan H; Guo Y; Ni S; Ling Y
Support Care Cancer; 2023 Apr; 31(5):303. PubMed ID: 37099077
[TBL] [Abstract][Full Text] [Related]
25. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N; Smith M
Front Immunol; 2022; 13():887866. PubMed ID: 35663947
[TBL] [Abstract][Full Text] [Related]
26. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Aggressive B Cell Lymphomas: Updates in 2019.
Mondello P; Nowakowski GS
Curr Hematol Malig Rep; 2020 Jun; 15(3):225-234. PubMed ID: 32372238
[TBL] [Abstract][Full Text] [Related]
28. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
[TBL] [Abstract][Full Text] [Related]
29. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
31. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
33. How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.
Logue JM; Chavez JC
Curr Treat Options Oncol; 2021 Oct; 22(12):112. PubMed ID: 34697650
[TBL] [Abstract][Full Text] [Related]
34. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Nuvvula S; Dahiya S; Patel SA
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
36. Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.
Zhu W; Tao S; Miao W; Liu H; Yuan X
Front Immunol; 2022; 13():894787. PubMed ID: 35757723
[TBL] [Abstract][Full Text] [Related]
37. [Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].
Zhang Q; Xiao Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):788-792. PubMed ID: 36709176
[No Abstract] [Full Text] [Related]
38. Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy.
Di Rocco A; Cuneo A; Di Rocco A; Merli F; De Luca G; Petrucci L; Ansuinelli M; Penna D; Rotondo F; Rigolin GM; Giaimo M; Re F; Farcomeni A; Martelli M; Foà R
Leuk Lymphoma; 2021 Apr; 62(4):828-836. PubMed ID: 33274677
[TBL] [Abstract][Full Text] [Related]
39. CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma.
Gambella M; Carlomagno S; Raiola AM; Giannoni L; Ghiggi C; Setti C; Giordano C; Luchetti S; Serio A; Bo A; Falco M; Della Chiesa M; Angelucci E; Sivori S
Front Immunol; 2022; 13():837457. PubMed ID: 35280988
[TBL] [Abstract][Full Text] [Related]
40. Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma.
Luo W; Li C; Wu J; Tang L; Wang X; Zhang Y; Wu Z; Huang Z; Xu J; Kang Y; Xiong W; Deng J; Hu Y; Mei H
Cytotherapy; 2023 Jul; 25(7):739-749. PubMed ID: 37074239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
